PubMed · 2006 · 10 citations · 11 references
MedicineEndocrinologyPharmacologyCell SignalingMolecular PharmacologySignal TransductionIon Channel PharmacologyIon Channel PhysiologyIon Channel RegulationIon Channel SignalingIon ChannelsPotassium Channel BiophysicsCurrentsInsulin Secretion EnhancementLigand SelectivityPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated ReceptorsPotassium Channel PharmacologyPotassium Channel PhysiologyPotassium Channel Regulation
Ligands for peroxisome proliferator-activated receptors alpha (PPARalpha) are clinically used for the treatment of patients with hyperlipidemia. As we have previously shown, a synthetic ligand of PPARalpha, fenofibrate, has a stimulatory effect on insulin secretion in clonal hamster insulinoma beta-cell line HIT-T15 cells. We have also demonstrated that fenofibrate directly inhibits ATP-sensitive potassium (K(ATP)) channels, an effect independent of PPARalpha. In this study, fenofibrate was shown to be able to reduce voltage-dependent K(+) (K(v)) channel currents in voltage-independent manner. Therefore, fenofibrate may modulate insulin secretion not only via inhibition of K(ATP) channels but also via reduction of the K(v) channel current.
11
Olivier Braissant, Fabienne Foufelle, Christian Scotto et al. · Endocrinology · 1996 · 2.1K citations